

CONTENTS

Cited in: BIOSIS/Biological Abstracts; CAB Abstracts; Chemical Abstracts Services; Current Contents (Life Sciences); EMBASE/Excerpta Medica; International Pharmaceutical Abstracts; PUBMED/MEDLINE/Index Medicus; Polymer Contents; Science Citation Index. Also covered in the abstract and citation database SCOPUS®. Full text available in ScienceDirect®

Cover Story

Human extracellular matrix powders for tissue engineering
I.C. Kwon (Seoul, Republic of Korea) 1

Research papers

Human extracellular matrix (ECM) powders for injectable cell delivery and adipose tissue engineering
J.S. Choi, H.-J. Yang, B.S. Kim, J.D. Kim, J.Y. Kim, B. Yoo, K. Park, H.Y. Lee and Y.W. Cho (Gyeonggi-do, Seoul, Republic of Korea; West Lafayette, IN, USA) 2

Encapsulation of low molecular weight heparins: Influence on the anti-Xa/anti-IIa ratio
L. Javot, T. Lecompte, M. Rabiskova and P. Maincent (Nancy, France; Brno, Czech Republic) 8

Basic fibroblast growth factor suspended in Matrigel improves titanium implant fixation in ovariectomized rats
Y. Gao, S. Zhu, E. Luo, J. Li, G. Feng and J. Hu (Chengdu, Taiyuan, China) 15

New formulation of vasoactive intestinal peptide using liposomes in hyaluronic acid gel for uveitis
L. Lajavardi, S. Camelo, F. Agnely, W. Luo, B. Goldenberg, M.-C. Naud, F. Behar-Cohen, Y. de Kozak and A. Bochot (Châtenay-Malabry, Paris, France) 22

High intensity focused ultrasound-responsive release behavior of PLA-b-PEG copolymer micelles
H. Zhang, H. Xia, J. Wang and Y. Li (Chengdu, China) 31

Gene Delivery

Functional polycarbonates and their self-assemblies as promising non-viral vectors
W.Y. Seow and Y.Y. Yang (Singapore, Singapore; London, United Kingdom) 40

Sustained viral gene delivery through core-shell fibers
L.-C. Liao, S. Chen, J.B. Liu and K.W. Leong (Durham, NC, Baltimore, MD, USA) 48

Nanomedicine

NGR-modified micelles enhance their interaction with CD13-overexpressing tumor and endothelial cells
X. Wang, Y. Wang, X. Chen, J. Wang, X. Zhang and Q. Zhang (Beijing, PR China) 56

Iontophoresis-driven penetration of nanovesicles through microneedle-induced skin microchannels for enhancing transdermal delivery of insulin
H. Chen, H. Zhu, J. Zheng, D. Mou, J. Wan, J. Zhang, T. Shi, Y. Zhao, H. Xu and X. Yang (Wuhan, China) 63

Liposome drugs' loading efficiency: A working model based on loading conditions and drug's physicochemical properties
D. Zucker, D. Marcus, Y. Barenholz and A. Goldblum (Jerusalem, Israel) 73

The effects of PEG grafting level and injection dose on gold nanorod biodistribution in the tumor-bearing mice
Y. Akiyama, T. Mori, Y. Katayama and T. Niidome (Fukuoka, Kawaguchi, Japan) 81

Calendar of Events

85



journal of controlled release

OFFICIAL JOURNAL OF THE CONTROLLED RELEASE SOCIETY
AND THE JAPANESE SOCIETY OF DRUG DELIVERY SYSTEM

JOURNAL OF CONTROLLED RELEASE

VOL. 139 (2009) P. 1-86

The diagram illustrates the process of creating human extracellular matrix powders for tissue engineering. It starts with a human figure, leading to a liposuction procedure. The resulting mixture is shown in a graduated cylinder, separated into three layers: Free oil (top), Adipose tissue (middle), and Blood (bottom). This mixture undergoes Homogenization/Centrifugation, resulting in a yellowish liquid. This liquid is then subjected to Freeze drying, resulting in a white, porous powder. Below the main process, four images are shown: a mouse, a fluorescence micrograph of green particles, a histological section of tissue (1 mm scale bar), and a higher magnification histological section (100 μm scale bar).

COVER STORY

Human extracellular matrix powders for tissue engineering




0168-3659(20091001)139:1;1-7

Available online at
ScienceDirect
www.sciencedirect.com

05054

ELSEVIER

journal of controlled release



Official Journal of the Controlled Release Society and of the Japanese Society of Drug Delivery System

The journal publishes innovative, original research involving the controlled release and delivery of drugs and other biologically active agents. The terms "controlled release" and "delivery" are used in their broadest sense to include mechanisms such as diffusion, chemical and enzymatic reactions, dissolution, osmosis, targeting, as well as the utilization and manipulation of biological processes. A broad spectrum of studies dealing with all aspects of controlled release and delivery, including gene delivery, tissue engineering and diagnostic agents, is encouraged. The use of prodrugs and carriers such as water-soluble polymers, micro and nanoparticles, liposomes and micelles is included in the scope.

In addition to original full length papers and reviews, the journal includes reports of future meetings and announcements pertaining to the activities of the Controlled Release Society. Persons considering writing a review are encouraged to contact the Review Editor.

EDITORS

EDITOR-IN-CHIEF

Prof. K. Park, Purdue University, Departments of Biomedical Engineering and Pharmaceutics, 206 S. Intramural Drive, West Lafayette, IN 47907, USA; E-mail: jcr-americas@aknainc.com

European Editor

Prof. T. Kissel, Department of Pharmaceutics & Biopharmacy, Phillips Universität, Marburg, Ketzlerbach 63, D-35037 Marburg, Germany; E-mail: jcr@staff.uni-marburg.de

European Associate Editor

Prof. S. De Smedt, Lab. of General Biochem. and Physical Pharmacy, University of Ghent, Harelbekestraat 72, B-9000 Ghent, Belgium

America Associate Editor

Prof. S.P. Schwendeman, Department of Pharmaceutical Sciences, University of Michigan, Ann Arbor, MI 48109-1065, USA

Asia Editor

Prof. I.C. Kwon, Biomedical Research Center, KIST, 39-1 Haweolgog-dong, Sungbook-ku, Seoul 136-791, Republic of South Korea

Asia Associate Editors

Prof. H. Harashima, Laboratory for Molecular Design of Pharmaceutics Faculty of Pharmaceutical Sciences, Hokkaido University Kita 12 Nishi 6, Sapporo City, Hokkaido 060-0812, Japan

Prof. A. Kikuchi, Department of Materials Science and Technology, Tokyo University of Science 2641 Yamazaki, Noda, Chiba 278-8510, Japan

Review Editor

Prof. V.P. Torchilin, School of Pharmacy, Bouve College of Health Sciences, Northeastern University, Mugar Building, Room 312, 360 Huntington, Ave., Boston, MA 02115, USA; E-mail: v.torchilin@neu.edu

Special Issue Editor

Prof. W.E. Hennink, Department of Pharmaceutics, University of Utrecht, Sorbonnelaan 16, 3508 TB Utrecht, The Netherlands

Advisor

Prof. T. Nagai, E-mail: nagai-t@mbc.ocn.ne.jp

Editorial Board

M.J. Alonso, Santiago de Compostela, Spain

Y.H. Bae, Salt Lake City, UT, USA

T.L. Bowersock, Kalamazoo, MI, USA

P. Colombo, Parma, Italy

P. Couvreur, Chatenay Malabry, France

M.C. Davies, Nottingham, UK

A.J. Domb, Jerusalem, Israel

R. Duncan, Cardiff, UK

B. Gander, Zürich, Switzerland

H. Ghandehari, Salt Lake City, UT, USA

G. Golomb, Jerusalem, Israel

D.W. Grainger, Fort Collins, CO, USA

R. Gurny, Geneva, Switzerland

M. Hashida, Kyoto, Japan

J.A. Hubbell, Lausanne, Switzerland

L. Illum, Nottingham, UK

S.Y. Jeong, Seoul, Korea

A. Kabanov, Omaha, NE, USA

Y. Kawashima, Gifu, Japan

J. Kopeček, Salt Lake City, UT, USA

G.S. Kwon, Madison, WI, USA

S.J. Lee, Seoul, Korea

C.M. Lehr, Saarbrücken, Germany

K.W. Leong, Baltimore, MD, USA

J.C. Leroux, Zürich, Switzerland

T. Li, Lexington, KY, USA

K. Mäder, Halle (Saale), Germany

H. Maeda, Kumamoto, Japan

A.G. Mikos, Houston, TX, USA

S. Mitragotri, Santa Barbara, CA, USA

R. Niven, Half Moon Bay, CA, USA

T. Okano, Tokyo, Japan

D.W. Pack, Urbana, IL, USA

T.G. Park, Daejeon, Korea

N.A. Peppas, Austin, TX, USA

Y. Perrie, Birmingham, UK

M. Prausnitz, Atlanta, GA, USA

D. Putnam, Ithaca, NY, USA

T. Rades, Dunedin, New Zealand

M.J. Rathbone, Hamilton, New Zealand

A.P. Rolland, San Diego, CA, USA

K. Roy, Austin, TX, USA

W.M. Saltzman, New Haven, CT, USA

R.A. Siegel, Minneapolis, MN, USA

J. Siewmann, Lille, France

P.S. Stayton, Seattle, WA, USA

Y. Sugiyama, Tokyo, Japan

K. Takayama, Tokyo, Japan

I. Uchegbu, London, UK

K. Ulbrich, Prague, Czech Republic

A. Urtti, Helsinki, Finland

E. Wagner, Munich, Germany

C. Wang, Minneapolis, MN, USA

Founding Editors

Prof. J. Feijen, University of Twente, The Netherlands

Dr. J. Heller, USA

INSTRUCTIONS FOR CONTRIBUTORS

Scope of the journal

The journal publishes papers innovative, original research involving the controlled release and delivery of drugs and other biologically active agents. The terms "controlled release" and "delivery" are used in their broadest sense to include mechanisms such as diffusion, chemical and enzymatic reactions, dissolution, osmosis, targeting, as well as the utilization and manipulation of biological processes. A broad spectrum of studies dealing with all aspects of controlled release and delivery, including gene delivery, tissue engineering and diagnostic agents, is encouraged. The use of prodrugs and carriers such as water-soluble polymers, micro and nanoparticles, liposomes and micelles is included in the scope. Papers that provide no new concepts or mechanistic insights will not be considered. The Letter of Submission should explain in one paragraph the originality and significance of the submitted work. The manuscript will not be processed without this information.

General procedures

The language of the journal is English. Manuscripts must be written in the third person and, when possible, in the past tense. Submission of a manuscript implies it is not under consideration for publication elsewhere and further, with the exception of review papers, original work not previously published is being presented. The Letter of Submission should explain in one paragraph the originality and significance of the submitted work. The manuscript will not be processed without this information.

Authors should submit their manuscripts electronically using the Elsevier submission site at <http://www.elsevier.com/locate/jconrel>

Manuscript Types

It is recommended that all articles do not exceed a total of 14 single-spaced, font size 12, typewritten pages, including references, tables, figure legends and figures. Review articles are allowed up to 28 pages. Please note that figures and tables should be embedded in the text as close as possible to where they are initially cited. It is also mandatory to upload separate graphic and table files as these will be required if your manuscript is accepted for publication.

Preparation of supplementary data. Elsevier accepts supplementary material to support and enhance your scientific research. Supplementary files offer the author additional possibilities to publish supporting applications, movies, animation sequences, high-resolution images, background datasets, sound clips and more. Supplementary files supplied will be published online only alongside the electronic version of your article in Elsevier Web products, including ScienceDirect: <http://www.sciencedirect.com>. In order to ensure that your submitted material is directly usable, please ensure that data is provided in one of our recommended file formats. Authors should submit the material in electronic format together with the article and supply a concise and descriptive caption for each file. For more detailed instructions please visit our artwork instruction pages at <http://www.elsevier.com/artworkinstructions>. For supplementary materials to be published in Journal of Controlled Release, text must be prepared with single space, and figures and tables should be inserted within the text of the supplementary materials.

Submission of Reviews

Authors should submit their manuscripts electronically using the Elsevier submission site at <http://authors.elsevier.com/journal/jconrel>. Persons considering submitting a 'Review' article must first contact the Review Editor – **Prof. V.P. Torchilin**, School of Pharmacy, Bouve College of Health Sciences, Northeastern University, Mugar Building, Room 312, 360 Huntington Ave., Boston, MA 02115, USA; e-mail: v.torchilin@neu.edu

Figures

Authors are requested to submit figures for a one-column width where possible and ensure that symbols, lettering and lines are sufficiently large and clear to be legible. Figure width is approximately 3 inches or 7.5 cm. If, together with your accepted article, you submit usable colour figures then Elsevier will ensure, at no additional charge, that these figures will appear in colour on the web (e.g., ScienceDirect and other sites) regardless of whether or not these illustrations are reproduced in colour in the printed version. For colour reproduction in print, you will receive information regarding the total cost from Elsevier after receipt of your accepted article. Consult the Guide for Authors (<http://www.elsevier.com/locate/jconrel>) for more detailed instructions.

Author enquiries: For enquiries relating to the submission of articles (including electronic submission where available) please visit this journals homepage at <http://www.elsevier.com/locate/jconrel>. You can track accepted articles at <http://www.elsevier.com/trackarticle> and set up e-mail alerts to inform you of when an article's status has changed. Also accessible from here is information on copyright, frequently asked questions and more.

Contact details for questions arising after acceptance of an article, especially those relating to proofs, are provided after registration of an article for publication.

Author corrections: Elsevier will do everything possible to get your article corrected and published as quickly and accurately as possible. *Therefore, it is important to ensure that all of your corrections are sent back to us in ONE communication.* Subsequent corrections will not be possible, so please ensure your first sending is complete.

Language services. Authors who require information about language editing and copyediting services pre- and post-submission please visit <http://www.elsevier.com/locate/languagepolishing> or our customer support site at <http://epsupport.elsevier.com>. Please note Elsevier neither endorses nor takes responsibility for any products, goods or services offered by outside vendors through our services or in any advertising. For more information please refer to our Terms & Conditions <http://www.elsevier.com/termsandconditions>

Funding body agreements and policies

Elsevier has established agreements and developed policies to allow authors whose articles appear in Journals Published by Elsevier, to comply with potential manuscript archiving requirements as specified as conditions of their grant awards. To learn more about existing agreements and policies please visit <http://www.elsevier.com/fundingbodies>

For a full and complete Guide for Authors, please refer to <http://www.elsevier.com/locate/jconrel>

JOURNAL OF CONTROLLED RELEASE HAS NO PAGE CHARGES

PRINTED BY POLESTAR WHEATONS LTD., EXETER, UK